BIL 010t

Drug Profile

BIL 010t

Alternative Names: Anti-nf-P2X7 antibody; BIL010t; BSCT 10% ointment

Latest Information Update: 02 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biosceptre International; Peptech UK
  • Developer Biosceptre International
  • Class Antibodies
  • Mechanism of Action Purinergic P2X7 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Basal cell cancer

Most Recent Events

  • 31 May 2016 Biosceptre plans a phase II trial for Basal cell cancer in the United Kingdom
  • 22 Jul 2014 Phase-I clinical trials in Basal cell cancer in Australia (Topical) prior to July 2014
  • 22 Jul 2014 Efficacy, safety and immunogenicity data from a phase I trial in Basal cell cancer released by Biosceptre
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top